July 09, 2025

ESC: Vaccines May Prevent Major Heart Events

A new ESC clinical statement finds that common vaccines, including those for influenza and COVID-19, may lower cardiovascular risks such as heart attack, stroke, and heart failure, particularly in high-risk patients.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

November 14, 2024

AI-Powered Camera Detects Hypertension, Diabetes

An AI-powered high-speed video camera offers quick, no-contact screenings for high blood pressure and diabetes by analyzing blood flow features in face and palm skin, achieving impressive accuracies.

Reuters

November 19, 2024

Wide Variation in SGLT2i Use Across U.S. Hospitals

Study reveals hospital variation in SGLT2i prescriptions, with only 11 of 518 hospitals (2.1%) achieving ≥50% prescription rates while 232 hospitals (44.8%) prescribed to fewer than 10% of eligible heart failure patients, highlighting an implementation gap in evidence-based therapy.

Conexiant

April 30, 2025

ApoB Count and Lp(a) Levels Key to CAD Risk

Total apoB particle count and Lp(a) levels best reflect coronary artery disease risk, with researchers noting that lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P.

Conexiant

May 30, 2025

Mepolizumab Reduces COPD Flares in Eosinophilic Patients

A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

March 13, 2025

Multivitamins After MI: Any Benefit for Patients with Diabetes?

The primary endpoint occurred in 35% of both the OMVM and placebo groups, according to a randomized trial evaluating multivitamins in post-MI patients with diabetes.

Conexiant